ADC Therapeutics SA (ADCT) Misses Q3 EPS by 1c; Reports $530.2M of Cash and Cash Equivalents

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to ADC Therapeutics SA (ADCT) Misses Q3 EPS by 1c; Reports $530.2M of Cash and Cash Equivalents

ADC Therapeutics SA (ADCT) Announces EU Medicines Agency Validates its Marketing Authorization Application for ZYNLONTA

October 29, 2021 7:16 AM EDT

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced its Marketing Authorization Application (MAA) for ZYNLONTA®, a CD19-targeted ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has been validated by the European Medicines Agency (EMA). Validation of the application enables the evaluation process by the EMAs Committee for Medicinal Products for Human Use (CHMP) to begin.

We continue to... More